Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
Please note: NECA will be closed from Friday 22nd December, reopening on Monday 8th January
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
  • Patients & Carers
  • Healthcare Professionals
  • Get Involved
  • What are Neuroendocrine Cancers?
  • What are Pheos & Paras?
  • NET Symptoms
  • Causes
  • Treatments
  • Grades
National Action Plan
  • Patient & Carer Support
  • Patient Resources
  • Optimal Care Pathway
  • NET Nurse
  • Patient Stories
  • Share your Story
  • Australian NET Specialists
  • Clinical Trials
  • Living with NETS
National Action Plan
  • Optimal Care Pathway
  • Professional Learning
  • Patient Referral
  • Clinical Trials
  • NET Symptoms
  • Australian NET Specialists
  • Request an In-Service
  • PLANET Registry
  • Order Booklets & Resources
National Action Plan
  • Advocate for Us
  • Share your Story
  • Donate
  • Fundraise
  • Events
  • In Memoriam
  • Corporate Partners
  • Gifts & Wills
  • Volunteer
National-Action-Plan-1.png
NET Nurse
Donate

Home » Education » AGITG Annual Scientific Meeting

AGITG Annual Scientific Meeting

  • August 29, 2019

Australasian Gastro-Intestinal Trials Group (AGITG) Annual Scientific Meeting (ASM), Adelaide Convention Centre 21 -23 August 2019 

Report by Meredith Cummins

The AGITG Annual Scientific Meeting was very well attended in Adelaide 21 – 23 August with 350 delegates registered. This meeting is a wonderful opportunity for health care professionals internationally and globally to network and work collaboratively to improve cancer treatments. Prof Tim Price, Chair of AGITG has stated that “Cancer treatment advances are only as good as patients’ ability to access them. But for far too many patients, high quality cancer care and clinical trials are out of reach. We have much work to do before everyone with cancer has equal access to the best treatments and the opportunity to participate in research.” By working together as a community, Professor Price emphasised that we can find solutions that will help ensure that the advances needed can be achieved.” This encompasses the work of the AGITG.

The opening plenary session was Rare cancers, how can we do it better? The presentations were by guest international speakers Professor Christian Jobin (United States) who discussed “The large fingerprint of Intestinal Microbiota in cancer”, Professor Stephen J Wigmore (United Kingdom) “State of the Art Biliary Tract Cancers and Associate Professor Manisha Palta (United States) “combination of Radiation and Immunotherapy: Fact or Fiction. These topics, especially Microbiota whereby samples of gastrointestinal bacteria (stool) investigate the role of bacteria in cancer, created much discussion and were the focus of further sessions throughout the meeting.

Other international invited faculty were Professor James L. Abbruzzese (United States), Professor Sharon Gil (Canada) and Professor Florian Lordick (Germany).

On the Wednesday afternoon a multidisciplinary workshop was held which included management of operational pancreatic tumours. Neoadjuvant therapy and nutritional care. The Thursday afternoon session of New Concepts Symposium saw four concepts presented to the audience which then were voted upon as to whether to take the concept further. One of the presented concepts presented by Dr Mark McGregor was a Phase II study of oncolytic immunotherapy of metastatic neuroendocrine tumours using intralesional rose Bengal disodium in combination with Pembrolizumab – was given the best new concept  award. A/Prof Michael Michael also presented during the ASM the new concept study LuCAT.

On Friday morning AGITG Upper GI Cancer trials were presented including Control NETs by A/Prof David Wyld (Capecitabine ON Temazolamide Radionuclide therapy Octreotate Lutetium-177 Neuroendocine tumours study) which has closed to recruitment and, NABNEC by A/Prof Mustafa Khasraw (A Randomised Phase II Study of Nabpacitaxel in Combination with Carboplatin as first line Treatment of Gastrointestinal Neuroendocrine Carcinomas) which is still open to recruitment.

It was fabulous to participate in this meeting. Throughout the meeting the Unicorn Foundation was gratefully acknowledged for the ongoing funding for many NET trials which is vital to the advances in NET management.

Share this post

Subscribe to our eNews

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Recent posts

Sisters Full Moon Dip Fundraiser

November 28, 2023

Watercolours in Balmain fundraiser

November 21, 2023

CommNETS Conference – New Zealand

November 21, 2023

AGITG Annual Scientific Meeting – New Zealand

November 21, 2023
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousVideo to help pronounce “Neuroendocrine”
NextBrisbane NET Patient ForumNext

Related Posts

Launceston NET Patient Forum

Friday 27th October we held our first ever NET Patient forum in Launceston Tasmania. NET patients travelled from Tasmania wide to here their local NET

25,550+ Australians and counting: The growing need for neuroendocrine cancer care

This month the Manning River Times ran a featured article for NeuroEndocrine Cancer Australia titled, 25,550 Australians and counting: the growing need for neuroendocrine cancer

INCA Annual Summit 2023

The International Neuroendocrine Cancer Alliance (INCA) Annual Summit was held in Bologna on the 11 & 12 September 2023. It was such a productive 2

National Symptom Awareness Campaign

NECA launches its first National Awareness Campaign We are thrilled to have launched the National Awareness Campaign this month, with thanks to the Department of Health for

View All

Make a difference

How much do you wish to donate?
$50
$100
$250
$500
$1000
Other

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • What Are Neuroendocrine Cancers?​
  • What Are Pheos & Paras?
  • National Patient Awareness
  • What Are Neuroendocrine Cancers?​
  • What Are Pheos & Paras?
  • National Patient Awareness

Patients & Carers

  • Patient & Carer Support
  • Patient Resources
  • Optimal Care Pathway
  • NET Nurse
  • National Action Plan
  • Patient Stories
  • Share your story
  • Australian NET Specialists
  • Clinical Trials
  • Living with NETS
  • Patient & Carer Support
  • Patient Resources
  • Optimal Care Pathway
  • NET Nurse
  • National Action Plan
  • Patient Stories
  • Share your story
  • Australian NET Specialists
  • Clinical Trials
  • Living with NETS

Healthcare Professionals

  • Optimal Care Pathway
  • Professional Learning
  • Patient Referral
  • Clinical Trials
  • NET Symptoms
  • Australian NET Specialists
  • Request an In-Service
  • PLANET Registry
  • Order Booklets & Resources
  • Optimal Care Pathway
  • Professional Learning
  • Patient Referral
  • Clinical Trials
  • NET Symptoms
  • Australian NET Specialists
  • Request an In-Service
  • PLANET Registry
  • Order Booklets & Resources

Get Involved

  • Advocate for us
  • Share your story
  • Donate
  • Fundraise
  • Events
  • In Memoriam
  • Corporate Partners
  • Gifts & Wills
  • Volunteer
  • Advocate for us
  • Share your story
  • Donate
  • Fundraise
  • Events
  • In Memoriam
  • Corporate Partners
  • Gifts & Wills
  • Volunteer
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2023 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin

What's on?

Healthcare Professional Learning Modules.

Over 3,355 Healthcare Professionals Australia-wide have now enrolled in the free online, RACGP-approved Education Modules. Ask your GP to enrol today.

Get Involved